Frontida BioPharm has made an equity investment in Oncoceutics as part of a product development and commercialization agreement to advance the company’s lead compound. The full article can be found here.
ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression Pre-treatment gene expression of cancer stem cells may help predict response to ONC201 ONC201 may inhibit cancer stem cell self-renewals by altering their gene expression, according to a study published August 2, 2017 in the open-access journal PLOS ONE by Varun Vijay Prabhu from
Business Development